Results for Drug Delivery

Dr. Gottardi leads the Bioengineering and Biomaterials (Bio²) lab, collaborating on clinical and research efforts to offer engineering solutions for pediatric health, primarily treatments for airway disorders. Dr. Gottardi researches mechanisms of laryngotracheal pathologies, applies tissue engineering to improve pediatric conditions, develops new devices, and formulates controlled drug delivery systems to treat and improve patients’ lives.

Dr. Levy is the director of Cardiology Research, and also serves as program director of the Cardiology National Heart, Lung, and Blood Institute (NHLBI) Research Training Grant. His research interests are the pathophysiology of biomaterials used in medicine, basic mechanisms and novel therapies for heart valve disease, arterial angioplasty, local drug delivery, and nanomedicine. He also has experience over three decades in medical device development.

Dr. Chorny's research program focuses on nanomedicines as well as drug, cell, and gene delivery systems for treating proliferative disease. His current research specifically focuses on the use of nanoparticle-mediated delivery to solid tumors and site-specific delivery for cardiovascular disease.

Dr. Broedur’s research interests focus on nanoparticle drug delivery and cancer predisposition. He is also interested in identifying novel cancer predisposition genes, and developing enhanced surveillance techniques to identify cancer early in predisposed individuals with the hope of improving outcome and reducing side effects.

As director of the Center for Clinical Pharmacology, Dr. Zuppa has a dynamic research program that focuses on using clinical pharmacological modeling and simulation strategies to study the impact of critical illness on drug disposition in children.